DFW Vascular Group, Dallas, TX; Surgery, Methodist Dallas Medical Center, Dallas, TX; Crescent Medical Center Lancaster, Lancaster, TX.
DFW Vascular Group, Dallas, TX; Surgery, Methodist Dallas Medical Center, Dallas, TX; TCU School of Medicine, Ft. Worth, TX.
Ann Vasc Surg. 2021 May;73:185-196. doi: 10.1016/j.avsg.2020.11.023. Epub 2020 Dec 26.
Subclavian vein and brachiocephalic vein occlusions are challenging problems in dialysis patients with ipsilateral upper extremity (UE) vascular access or in need of one. HeRO grafts (Hemodialysis Reliable Outflow, Merit Medical Systems, Inc, South Jordan, UT) have been used to manage such occlusions but patients with chronic hypotension treated with HeRO graft may have threatened patency. We describe an alternative technique using a supraclavicular stent graft to reconstruct the venous outflow, evaluate outcomes of this procedure, and discuss its role in complex hemodialysis patients.
From January 2019 to January 2020, we performed open surgical and endovascular dialysis access procedures in 297 patients. Eight patients (2.7%) with failing or failed access and subclavian and or brachiocephalic vein occlusion were treated with supraclavicular stent graft placement. Mean age was 52 years, ranging from 32 to 70. Five patients had failed access and were dialyzed using catheters (two femoral). Three patients with failing fistulas had severe arm edema. Two patients had recurrent HeRO graft thrombosis. We performed a retrospective review of these 8 patients and evaluated access patency and complications.
Technical success and access function were 100% in all patients. One patient developed ischemic neuropathy and underwent proximalization of the arterial inflow with improvement. Already-existing fistulas were used for dialysis the day after the procedure and new grafts within 2-4 weeks. Arm edema resolved within one week after the procedure. Median follow-up was 254.5 days, range 24-408 days, with primary patency rate of 87.5% and secondary patency rate of 100%. Only one patient has required reintervention. Postoperative evaluation with ultrasound has revealed patent stent graft in the area of the subcutaneous cervical tunnel over the clavicle.
Supraclavicular stent graft placement to a central vein can be used successfully to reconstruct venous outflow in hemodialysis patients with complex central vein occlusions. A supraclavicular extra-anatomic path can be used safely and effectively to place new UE vascular access or salvage threatened access in this challenging patient population.
锁骨下静脉和头臂静脉阻塞是同侧上肢(UE)血管通路的透析患者或需要建立血管通路的透析患者面临的挑战。HeRO 移植物(Hemodialysis Reliable Outflow,Merit Medical Systems,Inc,南约旦,犹他州)已被用于治疗此类阻塞,但接受 HeRO 移植物治疗的慢性低血压患者可能存在通畅性受到威胁的情况。我们描述了一种使用锁骨下支架移植物重建静脉流出的替代技术,评估了该手术的结果,并讨论了其在复杂血液透析患者中的作用。
2019 年 1 月至 2020 年 1 月,我们对 297 例患者进行了开放手术和血管内透析通路手术。8 例(2.7%)因失功或失败的通路以及锁骨下和/或头臂静脉阻塞而接受锁骨下支架移植物置入术治疗。平均年龄为 52 岁,范围为 32 岁至 70 岁。5 例患者因通路失功而使用导管(2 例股部)进行透析。3 例瘘管功能不良的患者手臂严重肿胀。2 例患者出现 HeRO 移植物再发血栓形成。我们对这 8 例患者进行了回顾性分析,并评估了通路通畅性和并发症。
所有患者的技术成功率和通路功能均为 100%。1 例患者发生缺血性神经病,并通过近端化动脉入路改善。手术后当天即使用已存在的瘘管进行透析,新的移植物在 2-4 周内使用。术后 1 周内手臂肿胀消退。中位随访时间为 254.5 天,范围为 24-408 天,一期通畅率为 87.5%,二期通畅率为 100%。仅 1 例患者需要再次介入治疗。术后超声检查显示锁骨下皮下颈隧道内的支架移植物通畅。
锁骨下支架移植物置入中心静脉可成功用于重建复杂中心静脉阻塞的血液透析患者的静脉流出。锁骨下额外解剖路径可安全有效地用于该具有挑战性的患者群体中建立新的 UE 血管通路或挽救受威胁的通路。